Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA appro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Future Oncol
Main Authors: Zimmer, Alexandra S, Steinberg, Seth M, Smart, Dee Dee, Gilbert, Mark R, Armstrong, Terri S, Burton, Eric, Houston, Nicole, Biassou, Nadia, Gril, Brunilde, Brastianos, Priscilla K, Carter, Scott, Lyden, David, Lipkowitz, Stanley, Steeg, Patricia S
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2020
Assuntos:
Clinical Trial Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270957/
https://ncbi.nlm.nih.gov/pubmed/32270710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0094
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados